Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLO bitopertin study in EPP or XLP
2024-520407-27-00Phase 3Completed
- Sponsor
- Disc Medicine
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) comparing Bitopertin with Matching placebo (2 arms). Primary endpoints: Average monthly total time in sunlight without pain, Percent change in whole-blood metal-free PPIX and 1 more. Started Oct 2025; status: completed.
02
Drugs
bitopertin
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on 2024-520407-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520407-27-00.